Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Atea Pharmaceuticals, Inc. (AVIR) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Atea Pharmaceuticals, Inc. is a member of our Medical group, which includes 888 different companies and currently sits at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atea Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for AVIR's full-year earnings has moved 7.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.According to our latest data, AVIR has moved about 21% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5% on a year-to-date basis. This means that Atea Pharmaceuticals, Inc. is outperforming the sector as a whole this year.One other Medical stock that has outperformed the sector so far this year is Design Therapeutics, Inc. (DSGN). The stock is up 11.5% year-to-date.For Design Therapeutics, Inc., the consensus EPS estimate for the current year has increased 6.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).Breaking things down more, Atea Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 431 individual companies and currently sits at #154 in the Zacks Industry Rank. On average, stocks in this group have lost 3.2% this year, meaning that AVIR is performing better in terms of year-to-date returns. Design Therapeutics, Inc. is also part of the same industry.Investors interested in the Medical sector may want to keep a close eye on Atea Pharmaceuticals, Inc. and Design Therapeutics, Inc. as they attempt to continue their solid performance.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks